Project Grant R41DK139916
Award Date
6/20/25
Completion Date
5/31/26
Dollars Obligated
$350K
Awardee
Katharos, Inc. (XSTCCEP41DN1)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $704,672 Phase I Small Business Innovation Research (SBIR) grant under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) to Flowpoint Medical Inc. in Overland Park, Kansas. The grant supports the development of an implantable, self-sealing needle guide system to improve vascular access and safety for hemodialysis patients. The project aims to refine the manufacturability and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $299,999 Project Grant (CFDA 93.847) to Hibar Microsciences, LLC to develop a prototype for CLEAR, a novel hemodialysis cartridge designed to improve the clearance of protein-bound uremic toxins (PBUTs) from the blood of patients with end-stage renal disease. The key objectives are to: 1) Develop a method for immobilizing lipocalin proteins onto dialysis membrane matrices to enhance PBUT removal; 2) Create and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $499,890 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Pavaj Vascular Corporation to develop a novel therapy to prevent arteriovenous fistula (AVF) venous stenosis, a common complication in end-stage kidney disease patients requiring hemodialysis. The funding will support two main goals: 1) evaluating the stability and biocompatibility of a nanoparticle-based...
This $518,661 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to advance the design of hemodialysis cartridges beyond the focus on urea removal. The project will test a novel parallel-plate dialyzer design that controls shear forces to potentially reduce platelet activation and clotting risks for the 548,000 Americans who rely on dialysis. The award to Vanderbilt...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $591,844 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Allvivo Vascular, Inc. to develop a catheter end cap with an antimicrobial luminal insert. The goal is to reduce the risk of bloodstream infections in hemodialysis patients, which are a leading cause of hospitalization and death in this population. The proposed "Gatekeeper Antimicrobial...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Fibrotherapeutics Inc. a $675,480 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel therapeutic for chronic kidney disease (CKD). The grant aims to advance a modified, water-soluble, orally-active caveolin-1 scaffolding domain (CSD) peptide as a potential treatment for CKD. Key objectives include determining the therapeutic index of...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $298,371 to Anova Biomedical, Inc. to develop a new class of biodegradable and elastic vascular grafts for hemodialysis access. The key products and services to be delivered include: Refining manufacturing techniques to produce vascular grafts with distinct arterial and venous zones using a novel, fully...
This $1,145,486 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop novel peripherally acting CB1 neutral antagonists for the treatment of diabetic kidney disease (DKD). The awardee, Makscientific LLC, a for-profit R&D company, will design and synthesize new analogs of compound AM6588 to improve potency, selectivity, oral...
This Project Grant award of $647,486 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by Inlighta Biosciences LLC, a woman-owned small business, to design and develop calcium-sensing receptor (CaSR) targeted theragnostic agents. The primary objectives are to: 1) Optimize and determine CaSR agonist and antagonist analogs with optimal drug activity and...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $725,420 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop an optimized allysine-targeted positron emission tomography (PET) probe and validate it in animal models and human renal biopsy samples. The goal is to establish a non-invasive...